Evidence map›Paper›PMID 30463379›Full record

ArticleInternational journal of molecular sciences2018

Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int. J. Mol. Sci. 2017, 18, 401.

Anna M Serwotka-Suszczak, Alicja M Sochaj-Gregorczyk, Jerzy Pieczykolan, Daniel Krowarsch, Filip Jelen, Jacek Otlewski

Abstract readPublished Erratum
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Anna M Serwotka-SuszczakDepartment of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, 50-137 Wroclaw, Poland. aniaserwotka@wp.pl.
Alicja M Sochaj-GregorczykDepartment of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, 50-137 Wroclaw, Poland. alicja.sochaj-gregorczyk@uj.edu.pl.
Jerzy PieczykolanDrug Discovery Department, Adamed Group, 05-152 Czosnow, Poland. jerzy.pieczykolan@celonpharma.com.ORCID 0000-0002-5887-0952
Daniel KrowarschDepartment of Protein Biotechnology, Faculty of Biotechnology, University of Wroclaw, 50-137 Wroclaw, Poland. daniel.krowarsch@uwr.edu.pl.ORCID 0000-0003-2856-218X
Filip JelenResearch and Development Department, Pure Biologics Ltd., 54-427 Wroclaw, Poland. filip@purebiologics.com.
Jacek OtlewskiDepartment of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, 50-137 Wroclaw, Poland. jacek.otlewski@uwr.edu.pl.ORCID 0000-0001-8630-2891

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has been brought to our attention that the affiliation of Dr. Jerzy Pieczykolan at the time when he was responsible for the work described in the paper [...].

Identifiers

PMID30463379
PMCPMC6275007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.